证券代码：300534 证券简称：陇神戎发 公告编号：2025-077 产品名称：血液透析干粉 型号、规格： | 型号 | 组成 | 规格 | | 装量 | | --- | --- | --- | --- | --- | | | | A1/1 | 人份 | 1170.9g/袋 | | | A 干粉 | A2/5 | 人份 | 5854.5g/袋 | | | | A3/10 | 人份 | 11709g/袋 | | | | B1/1 | 人份 | 588g/袋 | | | | B2/5 | 人份 | 2940g/袋 | | | | B3/10 | 人份 | 5880g/袋 | | LS-F | | BD1/1 | 人份 | 680g/袋 | | | B 干粉 | BD2/1 | 人份 | 700g/袋 | | | | BD3/1 | 人份 | 720g/袋 | | | | BT1/1 | 人份 | 680g/瓶 | | | | BT2/1 | 人份 | 700g/瓶 | | | | BT3/1 | 人份 | 720g/瓶 | 甘肃陇神戎发药业股份有限公司 关于获得血液透析干粉医疗器械注册证的公告 本公司及董事会全 ...

Company Overview - Longshen Rongfa (SZ 300534) held its 24th meeting of the 5th Board of Directors on November 4, 2025, to discuss the adjustment of the special committee members [1] - As of the report date, Longshen Rongfa has a market capitalization of 3.1 billion yuan [1] Revenue Composition - For the first half of 2025, Longshen Rongfa's revenue composition is as follows: - Pharmaceutical sales accounted for 86.53% - Medical device sales accounted for 6.69% - Logistics and distribution accounted for 4.48% - Rental income accounted for 0.76% - Consulting services accounted for 0.7% [1] Industry Insights - A significant increase in overseas orders by 246% has been reported, covering over 50 countries and regions, indicating a booming industry [1] - Entrepreneurs have raised concerns about some companies selling products at a loss, warning of potential vicious competition expanding overseas [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-075 甘肃陇神戎发药业股份有限公司 2025年第五次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况 （一）会议召开情况 4.会议召集人：公司董事会 5.会议主持人：董事长康永红先生 6.本次股东会的召集、召开以及表决程序符合《公司法》等法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 1.会议召开时间： （1）现场会议召开时间：2025 年 11 月 4 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年11月4日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易所 互联网投票系统进行网络投票的时间为2025年11月4日9:15—15:00期间的任意 时间。 2.现场会议地点：甘肃省兰州市榆中县定远镇国防路 10 号公司六楼会议室 3.会议召开方式：本次股东 ...

北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第五次临时股东会 之 法律意见书 甘肃省兰州市城关区雁园路 601 号甘肃省商会大厦 A 座 15 层 邮编：730030 电话：（0931）8260111 传真：（0931）8456612 本所律师列席了贵公司本次股东会，并根据本法律意见书出具日前已发生或 存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》以及《甘肃 陇神戎发药业股份有限公司章程》（以下简称《公司章程》）等有关法律、法规 和规范性文件的有关规定出具本法律意见书。 为出具本法律意见书，本所律师审查了本次股东会的有关文件和材料。本所 律师已得到贵公司保证，其已提供了本所律师认为出具法律意见书所必需的材料， 其所提供的原始材料、副本、复印件等材料、口头证言均真实、准确、完整，有 关副本、复印件等材料与原始材料一致。 在本法律意见书中，本所律师仅就本次股东会的召集、召开程序、出席会议 人员的资格、召集人资格及会议表决程序、表决结果是否符合《公司法》《上市 公司股东会规则》等法律、法规、规范性文件 ...

二、董事会会议审议情况 证券代码：300534 证券简称：陇神戎发 公告编号：2025-076 甘肃陇神戎发药业股份有限公司 第五届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届董事会第二十 四次会议于 2025 年 11 月 4 日在公司六楼会议室现场召开，本次会议以豁免通知 时限形式于 2025 年 11 月 4 日以书面形式通知全体董事。本次会议由公司董事长 康永红先生主持，应出席会议董事 9 人，实际出席会议董事 9 人，公司高级管理 人员列席了会议。本次会议的召集、召开符合《公司法》等有关法律、行政法规、 部门规章和《公司章程》的相关规定，合法有效。 会议审议并通过了如下议案： 1.审议通过《关于调整公司第五届董事会专门委员会委员的议案》 鉴于公司独立董事人员发生变动，为完善公司治理结构，董事会同意补选独 立董事方文彬先生接替已离任独立董事李宗义先生担任第五届董事会审计委员 会主任委员及薪酬与考核委员会委员职务，任期与第五届董事会一致，董事会 ...

Core Viewpoint - The stock of Longshen Rongfa has shown fluctuations in recent trading sessions, with a year-to-date increase of 16.17% but a slight decline in the last five days, indicating mixed market sentiment towards the company [1][2]. Financial Performance - For the period from January to September 2025, Longshen Rongfa reported a revenue of 647 million yuan, representing a year-on-year decrease of 19.71%. However, the net profit attributable to shareholders increased by 9.13% to 27.03 million yuan [2]. - Cumulatively, the company has distributed 42.64 million yuan in dividends since its A-share listing, with 24.27 million yuan distributed over the past three years [3]. Shareholder Information - As of October 20, 2025, the number of shareholders for Longshen Rongfa increased to 27,800, up by 2.21% from the previous period. The average number of circulating shares per shareholder decreased by 2.16% to 10,866 shares [2]. - Among the top ten circulating shareholders, the Huatai-PB Zhongzheng Traditional Chinese Medicine ETF holds 1.33 million shares, an increase of 351,800 shares compared to the previous period [3]. Market Activity - On October 31, the stock price of Longshen Rongfa rose by 2.03% to 10.06 yuan per share, with a trading volume of 33.21 million yuan and a turnover rate of 1.10%. The total market capitalization stands at 3.052 billion yuan [1]. - The net inflow of main funds was 1.6073 million yuan, with large orders accounting for 15.07% of total purchases [1]. Business Overview - Longshen Rongfa, established on June 3, 2002, and listed on September 13, 2016, is primarily engaged in the production and sales of traditional Chinese medicine. The revenue breakdown includes 86.53% from pharmaceutical sales, 6.69% from medical devices, and smaller contributions from logistics, rental, and consulting services [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [1].

甘肃陇神戎发药业股份有限公司 关于控股子公司收到药品注册上市许可申请 《受理通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，甘肃陇神戎发药业股份有限公司控股子公司甘肃普安制药股份有限公 司（以下简称"普安制药"）收到国家药品监督管理局下发的布瑞哌唑口溶膜境 内药品注册上市许可申请的《受理通知书》，现将相关情况公告如下： 一、《受理通知书》主要信息 （一）申请单位：甘肃普安制药股份有限公司 申请事项：境内生产药品注册上市许可 产品名称：布瑞哌唑口溶膜 规格：2mg 证券代码：300534 证券简称：陇神戎发 公告编号：2025-074 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决 定予以受理。 （二）申请单位：甘肃普安制药股份有限公司 申请事项：境内生产药品注册上市许可 产品名称：布瑞哌唑口溶膜 规格：1mg 受理号：CXHS2500132 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决 定予以受理。 产品名称：布瑞哌唑口溶膜 受理号：CXHS2500131 （三）申请单位：甘肃普安制药股份有限公司 申请事项： ...

Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. reported steady growth in revenue and net profit for the first three quarters of 2025, driven by the recovery of the traditional Chinese medicine industry and the enhancement of its core product competitiveness [1][2]. Financial Performance - The company achieved an operating income of 647 million yuan and a net profit attributable to shareholders of 27.03 million yuan, representing a year-on-year increase of 8.11% [1]. - The net profit excluding non-recurring gains and losses was 28.71 million yuan, up 31.14% year-on-year [1]. Market Position and Product Development - Longshen Rongfa has focused on optimizing its market sales layout, consolidating the market share of its core products, and exploring the market potential of existing generic drugs [2]. - The company’s two exclusive products, Yuanhu Zhitong Pill and Xuanfei Zhike Mixture, have seen increased market competitiveness and brand influence, ranking in the top 20 for various categories in public medical institutions [2]. Production Capacity and R&D - A new production line for the Xuanfei Zhike Mixture has been established, capable of producing 50 million boxes annually, ensuring a solid supply for the market [3]. - The company emphasizes product R&D as a core driver of sustainable development, with ongoing projects for product development and clinical trials [3]. Future Outlook - The company plans to continue focusing on traditional Chinese medicine, enhancing market development and research efforts to promote sustainable growth [3].

Group 1 - The core point of the article is that Longshen Rongfa reported a decline in revenue for the first three quarters of 2025, while net profit attributable to shareholders increased [1] Group 2 - For the first three quarters of 2025, the company achieved operating income of 647,287,705.63 yuan, representing a year-on-year decrease of 16.12% [1] - The net profit attributable to shareholders was 27,029,405.74 yuan, showing a year-on-year growth of 8.11% [1]

Core Viewpoint - The company reported steady growth in its operating performance for the first three quarters of 2025, driven by the recovery of the traditional Chinese medicine industry and the enhancement of its core product competitiveness [1] Financial Performance - The company achieved operating revenue of 647 million yuan and a net profit attributable to shareholders of 27.03 million yuan, representing a year-on-year increase of 8.11% [1] - The net profit after deducting non-recurring gains and losses was 28.71 million yuan, showing a year-on-year growth of 31.14% [1] Product Development and Market Position - The company focuses on the development of traditional Chinese medicine, with core products such as Yuanhu Zhitong Pill and Xuanfei Zhike Decoction gaining market share and brand influence [2] - Yuanhu Zhitong Pill ranked 15th in the "Top 20 Sales of Traditional Chinese Medicine Pills in Public Medical Institutions" for the first half of 2024, while Xuanfei Zhike Decoction ranked 6th in the "Top 20 Cough and Phlegm Relief Traditional Chinese Medicines" [2] - The company is advancing the secondary development of its main products, including real-world studies for Xuanfei Zhike Decoction and Yuanhu Zhitong Pill, and is progressing with the construction of a production line for blood dialysis concentrate [3] Strategic Focus - The company will continue to concentrate on its core business of traditional Chinese medicine, enhancing market development and research efforts to promote sustainable growth [4]